Compare Novartis AG (NVS) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Rigetti Computing Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Rigetti Computing Inc trades at $14.02 (market cap $4.72B). The key difference: Novartis AG is far larger — about 56.9× Rigetti Computing Inc's market cap, and Novartis AG pays a 3.31% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Rigetti Computing Inc for 35 Days on average.
| NVS | RGTI | |
|---|---|---|
Market Cap | $268.57B | $4.72B |
Volume | 1,532,573 | 17,136,381 |
Sector | Health | Technology |
52-Week High | $168.62 | $56.34 |
52-Week Low | $121.80 | $12.90 |
Typical Hold Time | 82 Days | 35 Days |
Enterprise Value | $309.89B | $4.33B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
RGTI trades at $14.03, down 3.84% with bearish technical signals despite bullish oscillators. The company shows minimal revenue of $7.09M (2025) with significant losses (-$216.21M net income) and negative margins. Analyst consensus remains strong with 85.71% buy ratings and $21.67 price target, while recent news highlights quantum computing sector momentum and Rigetti's hybrid quantum-HPC partnerships.
RGTI presents high-risk speculative potential with Wall Street optimism contrasting weak fundamentals. The stock offers substantial upside to analyst targets but faces execution risks in commercializing quantum technology amid persistent cash burn and competitive pressures from better-funded peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
